# NervGen Pharma Corp.
Based in Vancouver, British Columbia, NervGen Pharma is a clinical-stage biotechnology company focused on developing pharmaceutical treatments designed to promote nervous system repair following neurotrauma and in neurologic disease states. The company pursues a drug discovery and development model, with commercialization as a longer-term objective.
The company's lead program, NVG-291, is currently in Phase 1b/2a clinical development for multiple indications including spinal cord injury, stroke, multiple sclerosis, and Alzheimer's disease. A secondary candidate, NVG-300, is being evaluated in preclinical models of ischemic stroke and confirmatory spinal cord injury studies. NervGen's development efforts are supported through a licensing agreement with Case Western Reserve University, which grants rights to develop and commercialize patented technology applicable to spinal cord injury and related nerve damage conditions.
The company was incorporated in 2017 and operates as a pre-revenue entity typical of early-stage biotechnology firms. Detailed information on employee headcount and geographic operations beyond the Canadian headquarters is not publicly available. Revenue generation remains dependent on successful clinical progression and eventual regulatory approval of its product candidates.
No 10-K filings found.